31-07-2025
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. ('Medicenna' or the 'Company') (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced grant of five patents covering the Company's IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna's intellectual property (IP) position across key markets and further support the Company's lead clinical and preclinical programs.
The newly granted patents cover composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines. Newly granted patents span major markets, with anticipated expiration dates ranging from 2033 to 2040 depending on the specific case and local rules, without accounting for any potential extensions.
